Is Invivyd going out of business?

INVIVYD, INC. (IVVD) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

INVIVYD, INC. (IVVD) scores 21 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Shares dilution YoY: 162.68% (YoY)

Five questions, kept separate

Survival - Stable

28+ mo of estimated runway from 2026-06-30, based on $160M of cash and short-term investments against $58.3M of annual burn. Adjusted shares outstanding increased 162.7% over the comparison year.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Undemanding

96.9% net-cash backing support an undemanding pre-commercial Valuation assessment.

Event risk - Evidence unavailable

No active asserted adverse event was found in the available filing evidence. The filing evidence is stale or incomplete, so this is not proof of absence.

What the rules read

• Shares dilution YoY: 162.68% (YoY)
• FCF margin: -109.10%
• Debt / Equity: -0.84x (Net Cash)
• ROIC: -154.24%
• Return on Assets: -23.98%
• Revenue Quality: High-quality (DSO -15d, Rev +21%)
• Revenue growth YoY: 21.20% (YoY) - Growth from a low base; sustainability uncertain.
• Cash Runway (years): 2.75y
• Revenue per Asset Efficiency: 14.79% QoQ (Improving)
• Cash Burn Deceleration: -94.87% QoQ improvement (Worsening)
• Working Capital Efficiency: 122.24x (Well-funded)
• Price / Sales: 4.3x (see Valuation)

Read from filings through 2026-08-13.

Price as of 2026-09-09.